Hologic rejects more than $ 16 billion in private TPG and Blackstone proposals, reports FT

ahsan65@gmail.comMay 27, 2025

0 0 3 minutes read

Hologic rejects more than $ 16 billion in private TPG and Blackstone proposals, reports FT

Real -time estimate CBOE BZX			Change of 5 days	Jan 1
62.94 ^USD	+ 15.96%		+ 11.27%	-12.84%

Posted on 05/27/2025 at 13:19

This article is reserved for members

Unlock the article: Register now!

Sector update: Financial	01:27	MT
Sector update: health care	01:21	MT
Hologic rejects more than $ 16 billion in private TPG and Blackstone proposals, reports FT	01:19	CONCERNING
Blackstone, TPG offers $ 16 billion to take an hological private	01:10 PM	MT
Hologic rejects $ 16 billion in private TPG and Blackstone, Financial Times	01:01	CONCERNING
Blackstone, TPG offers $ 16 billion to take an hological private	01h00	MT
Blackstone, TPG offers to take private hological reports in an agreement of $ 16 billion, Financial Times reports	12:57	MT
Blackstone, TPG offers $ 16 billion to take Hologic Private reports, Financial Times	12:55	MT
TPG and Blackstone offered $ 16 BLN to take the Hologic Private – FT health group	12:54	CONCERNING
BNP Paribas Exane adjusts the price target to Hologic at $ 71, compared to $ 85, maintains the outperformance rating	06:30	MT
Hologic to present new data to Asco 2025 strengthening the role of change in the practice of the breast cancer®? Test to help provide more personalized care to patients	Can. 22	Here
Hologic, Inc. present at RBC Capital Markets Global Healthcare Conference 2025, 20-20-2025 09:30 am	Can. 20
Stephens adjusts the hological price target to $ 70, compared to $ 77, maintains the overweight note	Can. 13	MT
Hologic Insider bought shares worth $ 300,760, according to a recent dry deposit	Can. 09	MT
Morgan Stanley reduces the price target on Hologic to $ 65, compared to $ 77, maintains the rating equal	Can. 05	MT
American capital indices jump following a strong report on jobs, softening the trade tensions of China	Can. 02	MT
Citigroup adjusts the Hological price target to $ 60, compared to $ 70	Can. 02	MT
Leerink Partners adjusts the hological price target to $ 60, compared to $ 65	Can. 02	MT
Jefferies adjusts the Hological price target to $ 65 from $ 78	Can. 02	MT
JPMorgan adjusts the price of Hologic price to $ 70 from $ 85	Can. 02	MT
Mizuho Securities Adjusts the price of Hological Price to $ 65, compared to $ 75	Can. 02	MT
Raymond James adjusts the Hological Price target to $ 71 from $ 90	Can. 02	MT
Evercore ISI adjusts the Hological Price target to $ 62, against $ 65	Can. 02	MT
Analysts recommendations: Amazon, Atlassian, Autozone, Block, Monster Beverage …	Can. 02
RBC reduces the price target on Hologic to $ 70, compared to $ 75, maintains the performance note in the sector	Can. 02	MT

Duration

Period

Holx: Dynamic graphic

Hologic, Inc. is the world leader in the design, manufacture and marketing of diagnostic products, medical imaging systems and surgical products dedicated to women’s health. Net sales are decomposed by the field of application as follows: – molecular diagnostics (44.2%): rapid diagnostic tests for the detection of human diseases (sexually transmitted infections, respiratory diseases, viral diseases, infectious diseases, cervical and prostate cervical cancers, etc.) and fetal fibronctin; – Mammary health (37.8%): solutions and systems of digital mammography and breast biopsy; -Gynecological surgery (15.9%): endometrial ablation devices, mini-invasive intervention systems for the hysteroscopic elimination of targeted intrauterine diseases (including fibroids and polyps). The group also offers fluid management systems to be used in hysteroscopic procedures; – Bone health (2.1%): bone imaging systems, bone soundometer and osteodensitometers for bone structure and density, and risk assessment of osteoporotic fractures. Net sales are broken down by source of income between product sales (80.8%) and services (19.2%). Net sales are geographically distributed as follows: the United States (75%), Europe (13.2%), Asia-Pacific (6.5%) and others (5.3%).

Learn more about the company

Sell